Currently, there are only two drugs for HFpEF: SGLT2 inhibitor and ARNI. The ALPK2/TPM1 regulatory axis may provide a unique therapeutic target for HFpEF, allowing the development of new treatment ...
In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback